ADGRL2

Across TCGA pan-cancer cohorts, ADGRL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ADGRL2 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADGRL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADGRL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where ADGRL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.831	0.971	<.001	62	view →
UCEC	DFS	Quartile	All	0.711	0.942	.016	20	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.860	.006	17	view →
CCRCC	DFS	Tertile	III,IV	0.831	0.303	.006	16	view →
GBM	OS	Quartile	All	1.000	0.871	.008	7	view →
PDAC	OS	Tertile	III,IV	0.233	0.546	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ADGRL2–LUAD (DFS)

Open the LUAD breakdown →